Probi probated reduce gut problems in connection with cancer radiotherapy. A randomized, double-blind, placebo-controlled trial with Probi's two probiotic strains, HEAL9TM and LP6595, was shown to reduce gastrointestinal problems for women receiving pelvic radiotherapy. The 3-armed study included 75 women with gynecological cancer receiving pelvic radiotherapy.

The patients were either given a high or a low dose of the combined probiotic strains HEAL9TM and LP6595 or placebo and was conducted on two sites in Sweden.